DOCSLIB.ORG

ANTIMICROBIAL AGENTS and CHEMOTHERAPY VOLUME 37 0 DECEMBER 1993 * NUMBER 12 Robert C

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ANTIMICROBIAL AGENTS and CHEMOTHERAPY VOLUME 37 0 DECEMBER 1993 * NUMBER 12 Robert C ANTIMICROBIAL AGENTS AND CHEMOTHERAPY VOLUME 37 0 DECEMBER 1993 * NUMBER 12 Robert C. Moellering, Jr., Barbara E. Murray, Editor (1997) Editor in Chief (1995) University of Texas Health Science New England Deaconess Hospital Thomas D. Gootz, Editor (1995) Center Boston, Mass. Pfizer Inc. Houston, Tex. Michael Barza, Editor (1995) Groton, Conn. Herbert A. Kirst, Editor (1996) New England Medical Center Frederick G. Hayden, Editor Lilly Research Laboratories Hospitals (1995) Indianapolis, Ind. Boston, Mass. University of Virginia Health Editor (1994) George L. Drusano, Editor (1998) Sciences Center Chinstine C. Sanders, University ofMaryland School of Charlottesville, Va. Creighton University School of Medicine Medicine Baltimore, Md. Omaha, Neb. EDITORIAL BOARD Robert D. Abbott (1993) George M. Eliopoulos (1994) Gary R. Matzke (1995) Charles Shipman, Jr. (1994) Vincent T. Andriole (1993) John N. Galgiani (1993) Douglas Mayers (1994) David M. Shlaes (1994) Peter C. Appelbaum (1994) N. H. Georgopapadakou (1994) Antone A. Medeiros (1993) Thomas R. Shryock (1995) Gordon L. Archer (1995) Dale N. Gerding (1994) Michael Miller (1993) Robert W. Sidwell (1993) Devron Averett (1993) Allan Godfrey (1993) Henry W. Murray (1993) Fritz Sorgel (1995) Masanori Baba (1995) Sherwood L. Gorbach (1995) John D. Nelson (1995) Philip J. Spagnuolo (1994) Frank Balis (1994) Stephen B. Greenberg (1995) Harold C. Neu (1995) P. Frederick Sparling (1993) Franklin A. Neva (1995) David P. Speert (1994) Arthur L. Barry (1995) Scott M. Hammer (1995) Lee Spruance John G. Bartlett (1993) Margaret R. Hammerschlag (1995) Wright Nichols (1995) Spotswood Arnold S. Bayer (1994) Robert E. W. Hancock (1995) Charles H. Nightingale (1993) (1995) A. Pachla (1993) Harold Standiford (1994) Michel G. Bergeron (1995) W. Lee Hand (1995) Lawrence David A. Stevens (1995) Richard F. Bergstrom (1994) H. Hunter Handsfield (1995) Joseph S. Pagano (1993) (1994) Charles W. Stratton (1994) Karen K. Biron (1993) Leonid B. Heifets (1993) Thomas R. Parr, Jr. Stephen E. Straus (1993) Jurg Blaser (1994) David C. Hooper (1993) James E. Pennington (1995) Alan M. Sugar (1995) Gerald P. Bodey (1995) Michael R. Jacobs (1993) T. J. Perun (1995) Richard B. Sykes (1994) Karen Bush (1994) George A. Jacoby (1995) Brent Petty (1995) Francis C. Szoka, Jr. (1995) Claude Carbon (1995) Susan E. Jensen (1994) Philip A. Pizzo (1994) Francis P. Tally (1993) Suzanne Chamberland (1995) James H. Jorgensen (1993) Ronald Polk (1993) Diane E. Taylor (1993) Henry F. Chambers (1994) A. W. Karchmer (1994) Catherine P. Reese (1995) Fred C. Tenover (1994) Sarah H. Cheeseman (1995) Donald Kaye (1994) Richard C. Reichman (1995) Clyde Thornsberry (1995) Anthony Chow (1994) Robert E. Kessler (1993) Douglas D. Richman (1993) Alexander Tomasz (1994) Donald M. Coen (1993) George S. Kobayashi (1994) Allan Ronald (1993) Roger D. Toothaker (1994) Patrice Courvalin (1994) Donald J. Krogstad (1995) John P. Rosazza (1995) Thomas Walsh (1995) William A. Craig (1993) Philip Todd Lavin (1995) John Rotschafer (1995) Bernard Weisblum (1994) William L. Current (1993) Marc LeBel (1994) Robert H. Rubin (1993) Peter F. Weller (1995) Michael H. Cynamon (1995) Stephen A. Lerner (1995) Merle Sande (1994) Richard J. Whitley (1993) William E. Dismukes (1993) Stuart B. Levy (1995) W. Eugene Sanders, Jr. (1993) Richard Wise (1995) Gary V. Doern (1993) David R. Luke (1993) W. Michael Scheld (1995) James Woodworth (1993) Michael N. Dudley (1995) Gerald L. Mandell (1995) Raymond F. Schinazi (1995) Lowell S. Young (1994) David Durack (1994) J. Joseph Marr (1995) Robert T. Schooley (1993) Geoffrey J. Yuen (1995) Theodore Eickhoff (1994) Henry Masur (1993) Richard S. Schwalbe (1994) Barbara H. Iglewski, Chairman, Publications Board Linda M. Illig, Director, Joumals Kathleen M. Whalen, Production Editor Antimicrobial Agents and Chemotherapy, an interdisciplinary publication of the American Society for Microbiology (ASM), 1325 Massachusetts Ave., N.W., Washington, DC 20005-4171, is devoted to the dissemination of knowledge relating to all aspects of antimicrobial, antiviral, antiparasitic, and anticancer agents and chemotherapy. Instructions to authors are published in the January issue each year; reprints are available from the editors and the Journals Division. AntimicrobialAgents and Chemotherapy is published monthly, one volume per year. The nonmember print subscription prices are $250 (U.S.) (Canadians add 7% GST) and $294 (other countries) per year; single copies are $40 (Canadians add 7% GST). The member print subscription prices are $49 (U.S.) (Canadians add 7% GST) and $84 (other countries; single copies are $10 (Canadians add 7% GST). For prices of CD-ROM versions, contact the Subscriptions Unit, ASM. Correspondence relating to scriptions, defective copies, missing issues, and availability of back issues should be directed to the Subscriptions Unit, ASM; correspondence relating to reprint orders should be directed to the Reprint Order Unit, ASM; and correspondence relating to disposition of submitted manuscripts, proofs, and general editorial matters should be directed to the Journals Division, American Society for Microbiology, 1325 Massachusetts Ave., N.W., Washington, DC 20005-4171. Phone: (202) 737-3600. Claims for missing issues from residents of the United States, Canada, and Mexico must be submitted within 3 months after publication of the issues; residents of all other countries must submit claims within 6 months of publication of the issues. Claims for issues missing because of failure to report an address change or for issues "missing from files" will not be allowed. Second-class postage paid at Washington, DC 20005, and at additional mailing offices. POSTMASTER: Send address changes toAntimicrobial Agents and Chemotherapy, ASM, 1325 Massachusetts Ave., N.W., Washington, DC 20005-4171. Made in the U.S.A. Printed on acid-free paper. ISSN 0066-4804 Copyright © 1993, American Society for Microbiology. CODEN: AMACCQ All Rights Reserved. the copyright owner's consent that copies of the article may be The code at the top of the first page of an article in this journal indicates stated for use or for personal use of specific clients. This consent is given on the condition, however, that the copier pay the made personal MA 01970, for copying beyond that permitted by Sections per-copy fee through the Copyright Clearance Center, Inc., 27 Congress St., Salem, for 107 and 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, advertising or promotional purposes, for creating new collective works, or for resale. Author Index Alcouloumre, Marcia S., 2628 Fallani, Stefania, 2693 Kondoh, Masumi, 2662 Reid, Carol D., 2606 Allen, Stanley D., 2716 Fich, Karen, 2550 Rice, Louis B., 2760 Aoki, Yuhko, 2656, 2662 Finegold, S. M., 2638 Lam, Patrick Y.-S., 2606 Rigon, Antonio, 2693 Arisawa, Mikio, 2656, 2662 Frachet, B., 2674 Larrick, James W., 2534 Roland, Gregory E., 2563 Ateshkadi, Arasb, 2650 Fraimow, Henry S., 2736 Lee, K., 2638 Rollwagen, Florence M., 2688 Franzini, P., 2545 Leggett, J., 2678 Rolston, Kenneth V., 2584 Bacheler, Lee T., 2606 French, Pamela, 2736 Le Gros, V., 2674 Rosenbaum, Beverly, 2584 Balzarini, Jan, 2540 Fukasawa, Masatomo, 2743 Lemmich, Else, 2550 Rosenberg, Ivan, 2540 Baqar, Shahida, 2688 Fukatsu, Hiroshi, 2756 Leser, Ulrike, 2612 Barmada, S., 2678 Levy, Stuart B., 2699 Sanada, Minoru, 2756 Beauchamp, Denis, 2727 Galgiani, John N., 2517 Lins, Ulysses, 2722 Sanders, Christine C., 2578 Becker, S. A. W. E., 2638 Garber, Sena, 2606 Lombardi, F., 2545 Sansano, Sebastiano, 2622 Bell, Constance A., 2668 Garcia, M. M., 2638 Louchahi, K., 2674 Sawada, Masashi, 2684 Benchimol, Marlene, 2722 Gaspar, Erzsebet, 2593 Scarnati, Helen, 2606 Bentorcha, Fairouze, 2593 Ghannoum, Mahmoud A., Maass, Gerhard, 2612 Schindler, Jay J., 2716 Bergeron, Michel G., 2727 2628 Manavathu, Elias K., 2645 Selan, L., 2618 Bergeron, Yves, 2727 Ghezzi, Pietro, 2527 Marshall, Steven A., 2747 Selsted, Michael E., 2628 Berlutti, F., 2618 Gilbert, D., 2678 Marshall, Steven H., 2760 Shafer, William M.j, 2710 Blais, Johanne, 2571 Gongalves, Noemia Mason, Edward O., Jr., 2522 Shimada, Hisao, 2656 Blom, Jens, 2550 Rodrigues, 2722 Matsuda, Kouji, 2756 Shimomoura, Yuko, 2534 Bodeau, Amy L., 2710 Goody, Roger, 2612 Maurin, M., 2633 Sironi, Marina, 2527 Borin, Marie T., 2650 Grewal, Jaswinder, 2645 McMurry, Laura M., 2699 Soussy, Claude J., 2588 Bradford, Patricia A., 2578 Guerry, Philippe, 2599 McNamara, Patrick J., 2706 Stair, Thomas O., 2754 Brion, N., 2674 McQueen, Teresa J., 2584 Stecca, Clara, 2693 Hand, Debra L., 2557 Mehta, Reeta T., 2584 Stoeckel, Klaus, 2706 Cantoni, Lavinia, 2527 Hand, W. Lee, 2557 Meservey, Mark A., 2563 Sumita, Yoshihiro, 2743 Carelli, Maria, 2527 Hansen, Lori M., 2699 Milocchi, Fabio, 2693 Summanen, P., 2638 Carey, Patrick M., 2650 Hara, Kohei, 2762 Mitsutake, Kotaro, 2762 Sutton, Lorraine, 2760 Carias, Lenore L., 2760 Hashizume, Terutaka, 2756 Miyasaki, Kenneth T., 2710 Tagliabue, G., 2545 Cesana, M., 2545 Hesse, Werner H., 2622 Miyazaki, Haruko M., 2762 Tanaka, Nobuo, 2756 Chamberland, Suzanne, 2571 Hirata, Michimasa, 2534 Miyazaki, Yoshitsugu, 2762 Tardif, Carole, 2571 Chen, Ming, 2550 Hirata, Takahiro, 2656 Morikawa, Keiko, 2684 Tardif, Manon, 2727 Christensen, S0ren Br0gger, Hirsh, Dwight C., 2699 Morikawa, Shigeru, 2684 Tarrand, Jeffrey J., 2584 2550 Holy, Antonin, 2540 Mueller, Barbara, 2612 Taylor, Diane E., 2645 Cohen, Michael A., 2563 Hoogkamer, Johannes F.
Load more

Recommended publications
  • Clinically Isolated Chlamydia Trachomatis Strains
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUIY 1988, p. 1080-1081 Vol. 32, No. 7 0066-4804/88/071080-02$02.00/0 Copyright © 1988, American Society for Microbiology In Vitro Activities of T-3262, NY-198, Fleroxacin (AM-833; RO 23-6240), and Other New Quinolone Agents against Clinically Isolated Chlamydia trachomatis Strains HIROSHI MAEDA,* AKIRA FUJII, KATSUHISA NAKATA, SOICHI ARAKAWA, AND SADAO KAMIDONO Department of Urology, School of Medicine, Kobe University, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe-city, Japan Received 9 December 1987/Accepted 29 March 1988 The in vitro activities of three newly developed quinolone drugs (T-3262, NY-198, and fleroxacin [AM-833; RO 23-6240]) against 10 strains of clinically isolated Chiamydia trachomatis were assessed and compared with those of other quinolones and minocycline. T-3262 (MIC for 90% of isolates tested, 0.1 ,ug/ml) was the most active of the quinolones. The NY-198 and fleroxacin MICs for 90% of isolates were 3.13 and 62.5 ,ug/ml, respectively. Recently, it has become well known that Chlamydia 1-ml sample of suspension was seeded into flat-bottomed trachomatis is an important human pathogen. It is respon- tubes with glass cover slips and incubated at 37°C in 5% CO2 sible not only for trachoma but also for sexually transmitted for 24 h. The monolayer was inoculated with 103 inclusion- infections, including lymphogranuloma venereum. In forming units of C. trachomatis. The tubes were centrifuged women, it causes cervicitis, endometritis, and salpingitis at 2,000 x g at 25°C for 45 min and left undisturbed at room asymptomatically (19), while in men it causes nongono- temperature for 2 h.
    [Show full text]
  • Repurposing Drug Scaffolds: a Tool for Developing Novel Therapeutics with Applications in Malaria and Lung Cancer
    Repurposing Drug Scaffolds: A Tool for Developing Novel Therapeutics with Applications in Malaria and Lung Cancer A Thesis Submitted by: Hannah Elizabeth Cook In partial fulfilment of the requirements for the degree of: Doctor of Philosophy September 2018 Supervisors: Professor Matthew J. Fuchter & Professor Anthony G. M. Barrett Department of Chemistry Imperial College London 2 Declaration of Originality I, Hannah Cook, hereby confirm that the work presented within this thesis is entirely my own, conducted under the supervision of Professor Matthew J. Fuchter and Professor Anthony G. M. Barrett, at the Department of Chemistry, Imperial College London, unless otherwise stated. All work performed by others has been acknowledged within the text and referenced where appropriate. Hannah E. Cook September 2018 Copyright Declaration The copyright of this thesis rests with the author and is made available under a Creative Commons Attribution Non-Commercial No Derivatives licence. Researchers are free to copy, distribute or transmit the thesis on the condition that they attribute it, that they do not use it for commercial purposes and that they do not alter, transform or build upon it. For any reuse or redistribution, researchers must make clear to others the licence terms of this work. 3 Abstract The definition of repurposing in the context of drug discovery encompasses a variety of strategies designed to redirect current therapeutic knowledge towards new disease indications. This approach can be successful for the design of new drugs to treat diseases of the developing world such as Malaria, where there are limited resources to fund new drug discovery campaigns. Moreover, it can be used to decrease the drug development time for diseases in which there is high drug attrition rates coupled with high mortality rates, which is the case for some cancers.
    [Show full text]
  • Treatment of Bacterial Urinary Tract Infections: Presence and Future
    european urology 49 (2006) 235–244 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review - Infections Treatment of Bacterial Urinary Tract Infections: Presence and Future Florian M.E. Wagenlehner *, Kurt G. Naber Urologic Clinic, Hospital St. Elisabeth, Straubing, Germany Article info Abstract Article history: Bacterial urinary tract infections (UTIs) are frequent infections in the Accepted December 12, 2005 outpatient as well as in the nosocomial setting. The stratification into Published online ahead of uncomplicated and complicated UTIs has proven to be clinically useful. print on January 4, 2006 Bacterial virulence factors on the one side and the integrity of the host defense mechanisms on the other side determine the course of the Keywords: infection. In uncomplicated UTIs Escherichia coli is the leading organism, Urinary tract infections (UTI) whereas in complicated UTIs the bacterial spectrum is much broader Uncomplicated and including Gram-negative and Gram-positive and often multiresistant complicated UTI organisms. The therapy of uncomplicated UTIs is almost exclusively Antibiotic resistance of antibacterial, whereas in complicated UTIs the complicating factors uropathogens have to be treated as well. There are two predominant aims in the Antibiotic treatment antimicrobial treatment of both uncomplicated and complicated UTIs: New antiinfectives for (i) rapid and effective response to therapy and prevention of recurrence treatment of UTI of the individual patient treated; (ii) prevention of emergence of resis- tance to antimicrobial chemotherapy in the microbial environment. The main drawback of current antibiotic therapies is the emergence and rapid increase of antibiotic resistance. To combat this development several strategies can be followed. Decrease the amount of antibiotics administered, optimal dosing, prevention of infection and development of new antibiotic substances.
    [Show full text]
  • A TWO-YEAR RETROSPECTIVE ANALYSIS of ADVERSE DRUG REACTIONS with 5PSQ-031 FLUOROQUINOLONE and QUINOLONE ANTIBIOTICS 24Th Congress Of
    A TWO-YEAR RETROSPECTIVE ANALYSIS OF ADVERSE DRUG REACTIONS WITH 5PSQ-031 FLUOROQUINOLONE AND QUINOLONE ANTIBIOTICS 24th Congress of V. Borsi1, M. Del Lungo2, L. Giovannetti1, M.G. Lai1, M. Parrilli1 1 Azienda USL Toscana Centro, Pharmacovigilance Centre, Florence, Italy 2 Dept. of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), 27-29 March 2019 Section of Pharmacology and Toxicology , University of Florence, Italy BACKGROUND PURPOSE On 9 February 2017, the Pharmacovigilance Risk Assessment Committee (PRAC) initiated a review1 of disabling To review the adverse drugs and potentially long-lasting side effects reported with systemic and inhaled quinolone and fluoroquinolone reactions (ADRs) of antibiotics at the request of the German medicines authority (BfArM) following reports of long-lasting side effects systemic and inhaled in the national safety database and the published literature. fluoroquinolone and quinolone antibiotics that MATERIAL AND METHODS involved peripheral and central nervous system, Retrospective analysis of ADRs reported in our APVD involving ciprofloxacin, flumequine, levofloxacin, tendons, muscles and joints lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin, prulifloxacin, rufloxacin, cinoxacin, nalidixic acid, reported from our pipemidic given systemically (by mouth or injection). The period considered is September 2016 to September Pharmacovigilance 2018. Department (PVD). RESULTS 22 ADRs were reported in our PVD involving fluoroquinolone and quinolone antibiotics in the period considered and that affected peripheral or central nervous system, tendons, muscles and joints. The mean patient age was 67,3 years (range: 17-92 years). 63,7% of the ADRs reported were serious, of which 22,7% caused hospitalization and 4,5% caused persistent/severe disability. 81,8% of the ADRs were reported by a healthcare professional (physician, pharmacist or other) and 18,2% by patient or a non-healthcare professional.
    [Show full text]
  • Preclinical Evaluation of Protein Disulfide Isomerase Inhibitors for the Treatment of Glioblastoma by Andrea Shergalis
    Preclinical Evaluation of Protein Disulfide Isomerase Inhibitors for the Treatment of Glioblastoma By Andrea Shergalis A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Medicinal Chemistry) in the University of Michigan 2020 Doctoral Committee: Professor Nouri Neamati, Chair Professor George A. Garcia Professor Peter J. H. Scott Professor Shaomeng Wang Andrea G. Shergalis [email protected] ORCID 0000-0002-1155-1583 © Andrea Shergalis 2020 All Rights Reserved ACKNOWLEDGEMENTS So many people have been involved in bringing this project to life and making this dissertation possible. First, I want to thank my advisor, Prof. Nouri Neamati, for his guidance, encouragement, and patience. Prof. Neamati instilled an enthusiasm in me for science and drug discovery, while allowing me the space to independently explore complex biochemical problems, and I am grateful for his kind and patient mentorship. I also thank my committee members, Profs. George Garcia, Peter Scott, and Shaomeng Wang, for their patience, guidance, and support throughout my graduate career. I am thankful to them for taking time to meet with me and have thoughtful conversations about medicinal chemistry and science in general. From the Neamati lab, I would like to thank so many. First and foremost, I have to thank Shuzo Tamara for being an incredible, kind, and patient teacher and mentor. Shuzo is one of the hardest workers I know. In addition to a strong work ethic, he taught me pretty much everything I know and laid the foundation for the article published as Chapter 3 of this dissertation. The work published in this dissertation really began with the initial identification of PDI as a target by Shili Xu, and I am grateful for his advice and guidance (from afar!).
    [Show full text]
  • The Effect of Chloramphenicol on BB88 Murine Erythroleukemia Cells
    Western Michigan University ScholarWorks at WMU Dissertations Graduate College 8-2007 The Effect of Chloramphenicol on BB88 Murine Erythroleukemia Cells Peter K. W. Harris Western Michigan University Follow this and additional works at: https://scholarworks.wmich.edu/dissertations Part of the Chemistry Commons Recommended Citation Harris, Peter K. W., "The Effect of Chloramphenicol on BB88 Murine Erythroleukemia Cells" (2007). Dissertations. 872. https://scholarworks.wmich.edu/dissertations/872 This Dissertation-Open Access is brought to you for free and open access by the Graduate College at ScholarWorks at WMU. It has been accepted for inclusion in Dissertations by an authorized administrator of ScholarWorks at WMU. For more information, please contact [email protected]. THE EFFECT OF CHLORAMPHENICOL ON BB88 MURINE ERYTHROLEUKEMIA CELLS by Peter K. W. Harris A Dissertation Submitted to the Faculty o f The Graduate College in partial fulfillment of the requirements for the Degree of Doctor of Philosophy Department of Biological Sciences Western Michigan University Kalamazoo, Michigan August 2007 Reproduced with permission of the copyright owner. Further reproduction prohibited without permission. THE EFFECT OF CHLORAMPHENICOL ON BB88 MURINE ERYTHROLEUKEMIA CELLS Peter K. W. Harris, Ph.D. Western Michigan University, 2007 DNA microarrays can be used to measure genome-wide transcript levels. These measurements may be useful in understanding cellular changes induced by a chemical agent. In this study, Affymetrix microarray technology has been used to study the effects of chloramphenicol, an antibiotic that inhibits bacterial and mitochondrial protein synthesis, on the transcription profile in mammalian cells. Transcript levels in BB88 murine erythroleukemia cells treated with 50 micromolar (pM) chloramphenicol, a concentration shown to inhibit BB 88 proliferation, are measured.
    [Show full text]
  • Antibiotic Dispensation Without a Prescription Worldwide: a Systematic Review
    antibiotics Review Antibiotic Dispensation without a Prescription Worldwide: A Systematic Review Ana Daniela Batista 1, Daniela A. Rodrigues 2 , Adolfo Figueiras 3,4,5 , Maruxa Zapata-Cachafeiro 3,4 ,Fátima Roque 2,6 and Maria Teresa Herdeiro 7,* 1 Department of Medical Sciences, University of Aveiro, 3810-193 Aveiro, Portugal; [email protected] 2 Research Unit for Inland Development, Polytechnic Institute of Guarda (UDI/IPG), 6300-559 Guarda, Portugal; [email protected] (D.A.R.); [email protected] (F.R.) 3 Department of Preventive Medicine and Public Health, University of Santiago de Compostela, 15702 Santiago de Compostela, Spain; adolfo.fi[email protected] (A.F.); [email protected] (M.Z.-C.) 4 Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiology and Public Health-CIBERESP), 28001 Madrid, Spain 5 Health Research Institute of Santiago de Compostela (IDIS), 15702 Santiago de Compostela, Spain 6 Health Sciences Research Centre, University of Beira Interior (CICS-UBI), 6200-506 Covilhã, Portugal 7 Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, 3810-193 Aveiro, Portugal * Correspondence: [email protected] Received: 7 October 2020; Accepted: 6 November 2020; Published: 7 November 2020 Abstract: Antibiotic resistance still remains a major global public health problem and the dispensing of antibiotics without a prescription at community pharmacies is an important driver of this. MEDLINE, Pubmed and EMBASE databases were used to search and identify studies reporting the dispensing of non-prescribed antibiotics in community pharmacies or drugstores that sell drugs for human use, by applying pharmacy interviews/questionnaires methods and/or simulated patient methods.
    [Show full text]
  • Guidelines on Urinary and Male Genital Tract Infections
    European Association of Urology GUIDELINES ON URINARY AND MALE GENITAL TRACT INFECTIONS K.G. Naber, B. Bergman, M.C. Bishop, T.E. Bjerklund Johansen, H. Botto, B. Lobel, F. Jimenez Cruz, F.P. Selvaggi TABLE OF CONTENTS PAGE 1. INTRODUCTION 5 1.1 Classification 5 1.2 References 6 2. UNCOMPLICATED UTIS IN ADULTS 7 2.1 Summary 7 2.2 Background 8 2.3 Definition 8 2.4 Aetiological spectrum 9 2.5 Acute uncomplicated cystitis in pre-menopausal, non-pregnant women 9 2.5.1 Diagnosis 9 2.5.2 Treatment 10 2.5.3 Post-treatment follow-up 11 2.6 Acute uncomplicated pyelonephritis in pre-menopausal, non-pregnant women 11 2.6.1 Diagnosis 11 2.6.2 Treatment 12 2.6.3 Post-treatment follow-up 12 2.7 Recurrent (uncomplicated) UTIs in women 13 2.7.1 Background 13 2.7.2 Prophylactic antimicrobial regimens 13 2.7.3 Alternative prophylactic methods 14 2.8 UTIs in pregnancy 14 2.8.1 Epidemiology 14 2.8.2 Asymptomatic bacteriuria 15 2.8.3 Acute cystitis during pregnancy 15 2.8.4 Acute pyelonephritis during pregnancy 15 2.9 UTIs in post-menopausal women 15 2.10 Acute uncomplicated UTIs in young men 16 2.10.1 Pathogenesis and risk factors 16 2.10.2 Diagnosis 16 2.10.3 Treatment 16 2.11 References 16 3. UTIs IN CHILDREN 20 3.1 Summary 20 3.2 Background 20 3.3 Aetiology 20 3.4 Pathogenesis 20 3.5 Signs and symptoms 21 3.5.1 New-borns 21 3.5.2 Children < 6 months of age 21 3.5.3 Pre-school children (2-6 years of age) 21 3.5.4 School-children and adolescents 21 3.5.5 Severity of a UTI 21 3.5.6 Severe UTIs 21 3.5.7 Simple UTIs 21 3.5.8 Epididymo orchitis 22 3.6 Diagnosis 22 3.6.1 Physical examination 22 3.6.2 Laboratory tests 22 3.6.3 Imaging of the urinary tract 23 3.7 Schedule of investigation 24 3.8 Treatment 24 3.8.1 Severe UTIs 25 3.8.2 Simple UTIs 25 3.9 References 26 4.
    [Show full text]
  • Original Article Fluoroquinolones Inhibit HCV by Targeting Its Helicase
    Antiviral Therapy 2012; 17:467–476 (doi: 10.3851/IMP1937) Original article Fluoroquinolones inhibit HCV by targeting its helicase Irfan A Khan1,2, Sammer Siddiqui1, Sadiq Rehmani1, Shahana U Kazmi2, Syed H Ali1,3* 1Department of Biological and Biomedical Sciences, Aga Khan University, Karachi, Pakistan 2Department of Microbiology, University of Karachi, Karachi, Pakistan 3Department of Microbiology, Dow University of Health Sciences, Karachi, Pakistan *Corresponding author e-mail: [email protected] Background: HCV has infected >170 million individuals of 12 different fluoroquinolones. Afterwards, Huh-7 and worldwide. Effective therapy against HCV is still lacking and Huh-8 cells were lysed and viral RNA was extracted. The there is a need to develop potent drugs against the virus. extracted RNA was reverse transcribed and quantified by In the present study, we have employed two culture models real-time quantitative PCR. Fluoroquinolones were also to test the activity of fluoroquinolone drugs against HCV: a tested on purified NS3 protein in a molecular-beacon- subgenomic replicon that is able to replicate independently based in vitro helicase assay. in the cell line Huh-8 and the Huh-7 cell culture model Results: To varying degrees, all of the tested fluoroqui- that employs cells transfected with synthetic HCV RNA to nolones effectively inhibited HCV replication in both produce the infectious HCV particles. Fluoroquinolones have Huh-7 and Huh-8 culture models. The inhibition of HCV also been shown to have inhibitory activity against certain NS3 helicase activity was also observed with all 12 of the viruses, possibly by targeting the viral helicase. To tease out fluoroquinolones.
    [Show full text]
  • FLUOROQUINOLONES: from Structure to Activity and Toxicity
    FLUOROQUINOLONES: from structure to activity and toxicity F. Van Bambeke, Pharm. D. & P. M. Tulkens, MD, PhD Unité de Pharmacologie Cellulaire et Moléculaire Université Catholique de Louvain, Brussels, Belgium SBIMC / BVIKM www.sbimc.org - www.bvikm.org www.md.ucl.ac.be/facm www.isap.org soon... Mechanism of action of fluoroquinolones: the basics... PORIN DNA Topo DNA gyrase isomerase Gram (-) Gram (+) 2 key enzymes in DNA replication: DNA gyrase topoisomerase IV bacterial DNA is supercoiled Ternary complex DNA - enzyme - fluoroquinolone DNA GYRASE catalytic subunits COVALENTLY CLOSED CIRCULAR DNA FLUOROQUINOLONES: DNA GYRASE ATP binding subunits 4 stacked molecules (Shen, in Quinolone Antimicrobial Agents, 1993) Resistance to fluoroquinolones: the basics decreased efflux pump permeability DNA mutation of DNA gyrase Topo isomerase the enzymes Gram (-) Gram (+) Fluoroquinolones are the first entirely man-made antibiotics: do we understand our molecule ? R5 O R COOH 6 R7 X8 N R1 Don’t panic, we will travel together…. Chemistry and Activity This is where all begins... The pharmacophore common to all fluoroquinolones BINDING TO DNA R5 O O R C 6 - BINDING TO O BINDING TO THE ENZYME THE ENZYME R7 X8 N R1 AUTO-ASSEMBLING DOMAIN (for stacking) From chloroquine to nalidixic acid... nalidixic acid N CH3 O O HN CH 3 C - O chloroquine CH N N Cl N 3 C2H5 1939 O O C O- 1962 Cl N 1958 C2H5 7-chloroquinoline (synthesis intermediate found to display antibacterial activity) Nalidixic acid * a • typical chemical features of O O fluoroquinolones (a, b, c) BUT a naphthridone C - O- b (N at position 8: ) H C N N 3 • limited usefulness as drug C H 2 5 • narrow antibacterial spectrum c (Enterobacteriaceae only) • short half-life (1.5h) • high protein binding (90%) * Belg.
    [Show full text]
  • Evaluation of Fleroxacin Activity Against Established Pseudomonas Fluorescens Biofilms D
    APPLIED AND ENVIRONMENTAL MICROBIOLOGY, May 1994, P. 1663-1669 Vol. 60, No. 5 0099-2240/94/$04.00+0 Copyright C 1994, American Society for Microbiology Evaluation of Fleroxacin Activity against Established Pseudomonas fluorescens Biofilms D. R. KORBER, 12* G. A. JAMES,1'3 AND J. W. COSTERTON2 Department of Biological Sciences, University of Calgary, Calgary, Alberta T2N 1N4,3 and Department ofApplied Microbiology and Food Science, University of Saskatchewan, Saskatoon, Saskatchewan 57N OWO,1 Canada, and Center for Biofilm Engineering, Montana State University, Bozeman, Montana 597172 Received 28 September 1993/Accepted 9 February 1994 Scanning confocal laser microscopy (SCLM) and fluorescent molecular probes were used to evaluate the effect of the fluoroquinolone fleroxacin on the architecture of established Pseudomonas fluorescens biofilms. Control P.fluorescens biofilms were heterogeneous, consisting of cell aggregates extending from the attachment surface to maximum measured depths of -90 ,im (mean biofilm depth at 72 h, 42 ± 28 ,um) and penetrated by an array of channels. In contrast, fleroxacin-treated biofilms were less deep (mean biofilm depth at 72 h, 29 + 8 ,um), varied little in depth over large areas, and consisted of a homogeneous distribution of cells. Fleroxacin also caused cells to elongate, with cells located near the biofilm-liquid interface lengthening significantly more than cells located at the attachment surface. By using SCLM, acridine orange, and image analysis it was found that -59%o of cells within fleroxacin-treated biofilms emitted red fluorescence whereas >99%6 of cells from control biofilms emitted green fluorescence. The fleroxacin-treated cells which emitted red fluorescence were observed to be the population of cells which elongated.
    [Show full text]
  • The Nitroimidazole Family of Drugs
    Br J Vener Dis: first published as 10.1136/sti.54.2.69 on 1 April 1978. Downloaded from British Journal of Venereal Diseases, 1978, 54, 69-71 Editorial The nitroimidazole family of drugs In 1955 an antibiotic complex isolated from a operative infection caused by susceptible anaerobes, strain of Streptomyces on the island of Reunion particularly in gynaecological surgery, appendi- was found by research workers of Rhone-Poulenc in cectomy, and colonic surgery. Paris to contain a trichomonacidal antibiotic- Real innovations in chemotherapy, such as azomycin. It had previously been isolated in Japan metronidazole, always attract attention from other (Maeda et al., 1953) and identified as 2-nitroimi- research groups. Although interest was slow to dazole (Ia see Table) (Nakamura, 1955). At the develop, research workers have sought analogous, time, and for some years after, this remarkably structurally-modified compounds which might afford simple compound defied synthesis, but it stimulated some advantage in clinical use-for example, the workers at Rhone-Poulenc to prepare and test greater potency, better tolerance and freedom from the activity of the more readily accessible isomeric side effects, a broader spectrum of action, a longer 5-nitroimidazoles (II). It was their good fortune in duration of action, or in some other characteristic. 1957 to find that these isomers were more active This effort has been concerned with important antiprotozoal agents than the natural product veterinary uses of 5-nitroimidazoles as well as the (Cosar and Julou, 1959). In a series of 150 related applications in human medicine. compounds, the one with a P-hydroxyethyl group Metronidazole has been a difficult target to in the 1-position gave the best compromise between improve upon, but several other drugs of this activity and toxicity and this brand of metroni- chemical family have been introduced to clinical dazole was introduced as Flagyl.
    [Show full text]